Novartis AG - HealthQuill

The US drug regulator gave its nod for Sandoz Inc., an arm of Sweden-based Novartis and which is set to be Europe’s largest generic drugmaker, for a biosimilar, Tyruko, to treat adults with multiple sclerosis.

USFDA green lights Sandoz’s biosimilar Tyruko to treat multiple sclerosis

HQ Team August 25, 2023: The US drug regulator gave its nod for Sandoz Inc., an arm of Sweden-based Novartis and which is.

by HealthQuill
August 25, 2023
0 Comments

Drugs Medical Pharma

Novartis sells eye business to Bausch+Lomb for $2.5 billion

HQ Team July 3, 2023: Swiss drugmaker Novartis is divesting its ophthalmology assets including Xiidra, an anti-inflammatory eye drop to Bausch + Lomb,.

by HealthQuill
July 3, 2023
0 Comments

Swiss drugmaker, Novartis signed a $3.5 billion deal with Chinook Therapeutics to boost the US-based company’s last-stage experimental trials of two drugs to treat chronic kidney diseases.

Drugs Health Pharma

Novartis to acquire Chinook Therapeutics in a $3.5 billion deal

HQ Team June 13, 2023: Swiss drugmaker, Novartis signed a $3.5 billion deal with Chinook Therapeutics to boost the US-based company’s last-stage experimental.

by HealthQuill
June 13, 2023
0 Comments

Novartis AG, the world's fourth-largest pharmaceutical company by revenue, announced its Kisqali drug reduced breast cancer recurrence when diagnosed at an early stage and has stopped its ongoing trial.

Drugs Pharma

Novartis AG stops breast cancer trial as it achieves early success

Novartis AG, the world's fourth-largest pharmaceutical company by revenue, announced its Kisqali drug reduced breast cancer recurrence when diagnosed at an early stage.